Genome Therapeutics Changes Name to Oscient Pharmaceuticals Corporation to Reflect Focus on Drug Development and Commercializati

14-Apr-2004

Waltham. - Genome Therapeutics Corp. , following the merger with Genesoft Pharmaceuticals and to better reflect its focus on drug development and commercialization, has received shareholder approval to change its name to Oscient Pharmaceuticals Corporation. The change to Oscient Pharmaceuticals (pronounced AWE-see-ent) will take effect immediately and the Company's stock will continue to trade on Nasdaq under the ticker symbol GENE.

"As we prepare for the launch of FACTIVE(R) tablets, we believe it is important for our new company name to more accurately reflect our mission and strategy," stated Steven M. Rauscher, President and CEO of Oscient Pharmaceuticals. "The name Oscient Pharmaceuticals, with its strong root in pharmaceutical science, reflects our continued commitment to the commercialization and clinical development of our pipeline."

At the Company's Annual Meeting held today in Boston, shareholders approved all five proposals presented for vote. Oscient's corporate headquarters will remain in Waltham, Massachusetts, with west coast offices in South San Francisco.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance